Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics and WuXi AppTec to Spend $2.8 Billion to Build Separate Singapore Facilities

publication date: Jul 22, 2022

WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. The sites will offer CRDMO (Contract Research, Development and Manufacturing Organization) services to each companies’ clients. Over the past few years, both companies have invested heavily to expand their physical presences around the globe while also incorporating new technologies. Their respective CEOs characterized the expansion into Singapore as the next logical step of their continuing growth globally. Although the two companies are separate, both operate under the umbrella of WuXi PharmaTech. More details....

Stock Symbols: (HK; 2269) (SHA: 603259)

Share this with colleagues: